A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors
| Protocol No. | PHO-NOVARTIS-ASC4KIDS | Scope | National |
|---|---|---|---|
| Principal Investigator | Rachael Schulte | Treatment Type | Treatment |
| Age Group | Children | Phase | Phase I/II |
